Stockscreener 앱 받기
115.87
1.03%
1.1096
전일 마감가:
$114.76
열려 있는:
$115.32
하루 거래량:
2.46M
Relative Volume:
0.28
시가총액:
$201.41B
수익:
$44.33B
순이익/손실:
$6.50B
주가수익비율:
31.17
EPS:
3.717
순현금흐름:
$7.40B
1주 성능:
+3.34%
1개월 성능:
+6.59%
6개월 성능:
-11.89%
1년 성능:
-14.72%
1일 변동 폭
$114.51
$116.53
1주일 범위
$111.18
$116.53
52주 변동 폭
$105.27
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
115.83 | 199.55B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
383.73 | 146.96B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
96.22 | 123.91B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
74.71 | 109.04B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.77 | 48.40B | 6.07B | 1.06B | 799.60M | 1.8527 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Pre-market: ABT.SW Abbott Laboratories (SIX) -12.00% to CHF88.00: watch CHF85.00 - Meyka
Abbott India: Quiet Rally In A Noisy MarketWhat US Investors Miss - AD HOC NEWS
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time - AOL.com
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time - The Motley Fool
Is Abbott Laboratories Stock Underperforming the Nasdaq? - Barchart.com
How The Evolving Wall Street Narrative Is Reframing Abbott Laboratories (ABT) Valuation Prospects - Yahoo Finance
Abbott Laboratories Secures Major Bond Issue to Fund Strategic Acquisition - AD HOC NEWS
Wrongful Death Case Tests Abbott’s FreeStyle Libre 3 Risk Oversight - simplywall.st
Abbott Laboratories Advances Major Acquisition Amid Market Scrutiny - AD HOC NEWS
Shanghai Henlius Biotech Expands Abbott License for HANSIZHUANG, Terminates KGBio Territories – Key Amendments and Market Impact 1234 - Minichart
Point of Care Diagnostics Market Competitive Landscape - GlobeNewswire
Point of Care Diagnostics Market Competitive Landscape Report 2025 Featuring Top 5 PlayersSysmex, Abbott Laboratories, Becton Dickinson and Co, Danaher, Quidel Diagnostics - Yahoo Finance Singapore
Exact Sciences shareholders give nod for acquisition by Abbott - Medical Buyer
Cardiac Marker Testing Market Is Going to Boom |• Abbott • Roche - openPR.com
Is Abbott Laboratories (ABT) Pricing Reflect Long Term Value After Recent Share Price Weakness - Yahoo Finance
Abbott Laboratories Launches Landmark $20 Billion Bond Offering - AD HOC NEWS
ABT.SW Abbott Laboratories (SIX) down 13.50% pre-market: CHF86.50 support to watch - Meyka
Abbott (ABT) Ascends While Market Falls: Some Facts to Note - Nasdaq
Abbott Labs: A boring dividend machine that could quietly make you rich - MSN
Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal - Bloomberg
Abbott Laboratories (ABT) Likely to Benefit From Nutrition Segment Recovery - Insider Monkey
Abbott Labs: A Boring Dividend Machine That Could Quietly Make You Rich - AOL.com
Key facts: Abbott Laboratories to raise $20 billion via bond sale; files for notes offering - TradingView
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Moves - simplywall.st
Abbott Laboratories (ABT) Investor Outlook: Exploring A Promising 18.87% Potential Upside - DirectorsTalk Interviews
Abbott lines up one of the year's biggest bond sales at $20B - Crain's Chicago Business
Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition - Quiver Quantitative
Abbott Laboratories (ABT) Plans $20B Bond Sale to Fund Exact Sci - GuruFocus
Exact Sciences Stockholders Approve Abbott Merger as Executive Pay Proposal Fails at Special Meeting - Yahoo Finance
Abbott Laboratories (ABT) Stock Price, Trades & News - GuruFocus
Abbott kicks off bond sale for Exact Sciences deal - Modern Healthcare News
Abbott (ABT) Submits Automatic Mixed Securities Shelf Filing - GuruFocus
Abbott seeks $20 billion in US bond sale for Exact Sciences dealBloomberg News - marketscreener.com
Abbott files for eight-part notes offering, size not disclosedSEC filing - marketscreener.com
Abbott Labs Commences 8-Part Bond Sale Tied to Exact Sciences Acquisition - marketscreener.com
Abbott Laboratories Commences 8-Part Bond Sale Tied to Exact Sciences Acquisition, Bloomberg Reports - marketscreener.com
Wrongful Death Suit Tests Abbott Libre 3 And Exact Sciences Ambitions - Yahoo Finance
Health and Wellness Industry Report 2026-2035: A $10.35+ - GlobeNewswire
Health and Wellness Industry Report 2026-2035: A $10.35+ Trillion Market by 2030 Featuring Major Players Such as with Abbott Laboratories, L'Oreal, Nestle, General Mills, Omron, Philips, J&J - Yahoo Finance UK
Cardiac Marker Testing Market Is Going to Boom | Roche • Abbott - openPR.com
Abbott Laboratories Secures Major Acquisition with Shareholder Approval - AD HOC NEWS
Abbott Laboratories $ABT Shares Sold by Tredje AP fonden - MarketBeat
Siligmueller & Norvid Wealth Advisors LLC Purchases Shares of 11,538 Abbott Laboratories $ABT - MarketBeat
Raiffeisen Bank International AG Purchases 33,095 Shares of Abbott Laboratories $ABT - MarketBeat
China Universal Asset Management Co. Ltd. Sells 15,607 Shares of Abbott Laboratories $ABT - MarketBeat
Rep. Thomas H. Kean, Jr. Purchases Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Pay Less, Gain More: STE, RMD Top Abbott Laboratories Stock - Trefis
Exact Sciences shareholders approve merger with Abbott Laboratories - Investing.com Australia
Decoding Abbott Laboratories (ABT): A Strategic SWOT Insight - GuruFocus
Exact Sciences shareholders approve merger with Abbott Laboratories By Investing.com - Investing.com India
Abbott (ABT) to Acquire Exact Sciences Following Stockholder App - GuruFocus
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
1.75%
자본화:
|
볼륨(24시간):